Reducing variation in the treatment of men with high risk/locally advanced prostate cancer NPCA Quality Improvement Workshop, 16.12.21
Impact of the Covid-19 pandemic: findings from the National Prostate Cancer Audit Julie Nossiter, NPCA Audit Lead, RCSEng/ Assistant professor, LSHTM
Update on NHS England’s Data and Action Plan Peter Johnson, National Clinical Director for Cancer, NHS England/ Professor of Medical Oncology, University Hospital, Southampton
Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England Matt Parry, NPCA Clinical Fellow/ Urology Registrar
Optimising the management of patients with high risk/locally advanced disease – improving the outcomes of older men Danielle Harari, Geriatric-oncology Consultant and Clinical Lead, Geriatric Oncology liaison Development Team, Guy’s and St. Thomas’
Panel discussion highlights: Determinants of variation in the treatment of high risk/locally advanced prostate cancer
How do we reduce variation in access to treatment for all men? The experience of black and ethnic minority groups Jonathan Makanjuola, Consultant Urological Surgeon, King's College Hospital
Reducing treatment-related toxicity after radical prostate cancer treatment A national quality improvement workshop for clinicians